Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) EBT (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed EBT for 9 consecutive years, with -$128.4 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 12.0% to -$128.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$512.4 million, a 21.23% decrease, with the full-year FY2025 number at -$512.4 million, down 21.23% from a year prior.
  • EBT was -$128.4 million for Q4 2025 at Denali Therapeutics, down from -$126.9 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $183.4 million in Q2 2023 to a low of -$133.0 million in Q1 2025.
  • A 5-year average of -$85.7 million and a median of -$100.6 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: surged 398.59% in 2023, then tumbled 154.0% in 2024.
  • Denali Therapeutics' EBT stood at -$75.8 million in 2021, then plummeted by 30.13% to -$98.7 million in 2022, then tumbled by 34.34% to -$132.6 million in 2023, then grew by 13.49% to -$114.7 million in 2024, then dropped by 12.0% to -$128.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's EBT are -$128.4 million (Q4 2025), -$126.9 million (Q3 2025), and -$124.1 million (Q2 2025).